Table 4 Multivariate regression analysis to determine the influence of all baseline variables on symptom worsening (WOMAC > 9 points) and structural progression (JSN > 0.7 mm) over 24 months
Variable of interest | Symptom worsening (WOMAC > 9 points) | Structural progression (JSN > 0.7 mm) | ||||
|---|---|---|---|---|---|---|
Odds ratio | 95% CI | p value | Odds ratio | 95% CI | p value | |
Baseline WOMAC* | 0.97 | 0.95–0.98 | < 0.001 | 1.01 | 1.00–1.02 | 0.16 |
Baseline JSN | 0.95 | 0.80–1.13 | 0.53 | 1.06 | 0.89–1.27 | 0.50 |
Age | 0.99 | 0.96–1.02 | 0.41 | 1.01 | 0.98–1.04 | 0.56 |
Gender | 1.46 | 0.90–2.37 | 0.13 | 1.18 | 0.70–1.98 | 0.53 |
BMI* | 1.06 | 1.01–1.11 | 0.01 | 1.02 | 0.97–1.07 | 0.39 |
Co-morbidities | 1.10 | 0.90–1.40 | 0.45 | 0.89 | 0.66–1.16 | 0.36 |
Race | 0.76 | 0.47–1.24 | 0.27 | 1.15 | 0.67–1.96 | 0.62 |
Employment | 0.63 | 0.38–1.05 | 0.07 | 1.22 | 0.70–2.12 | 0.49 |
Smoker | 1.25 | 0.82–1.92 | 0.30 | 1.30 | 0.82–2.06 | 0.27 |
Previous knee surgery | 1.19 | 0.70–2.00 | 0.52 | 0.97 | 0.56–1.69 | 0.91 |
mLPFA | 1.03 | 0.99–1.06 | 0.18 | 1.02 | 0.98–1.06 | 0.39 |
mLDFA | 0.92 | 0.84–1.01 | 0.09 | 1.05 | 0.95–1.16 | 0.35 |
MPTA** | 1.05 | 0.96–1.15 | 0.31 | 0.79 | 0.71–0.88 | < 0.001 |
mLDTA | 1.02 | 0.96–1.08 | 0.59 | 1.02 | 0.96–1.08 | 0.50 |